VIVS VivoSim Labs, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1497253 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.6%
TTM net income YoY-417.8%
TTM EPS YoY-768.6%
Revenue 3-yr CAGR-28.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,897.8%
Net margin-7,605.9%
FCF margin-7,618.5%
EBITDA margin-8,771.9%
Returns
ROE-143.5%
ROA-104.7%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.50x
Interest coverage-1,001.00x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue63.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $131,000 | $144,000 | $109,000 | $370,000 | $1.50M |
| Cost of revenue | $0 | $5,000 | — | — | — |
| Gross profit | $131,000 | $139,000 | — | — | — |
| R&D expense | $4.19M | $5.03M | $5.50M | $8.88M | $3.32M |
| SG&A expense | $7.43M | $7.73M | $9.70M | $9.22M | $9.66M |
| Operating income | -$11.49M | -$12.62M | -$15.09M | -$17.73M | -$11.48M |
| Interest expense | $12,000 | $10,000 | — | — | — |
| Pretax income | -$13.84M | -$2.49M | — | — | — |
| Income tax | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 |
| Net income | -$13.84M | -$2.49M | -$14.67M | -$17.26M | -$11.45M |
| EBITDA | -$11.27M | -$12.35M | -$14.81M | -$17.44M | -$11.34M |
| EPS (basic) | -5.35 | -1.70 | -19.25 | -1.98 | -1.32 |
| EPS (diluted) | -5.35 | -1.70 | -19.25 | -1.98 | -1.32 |
| Weighted avg. shares (diluted) | 2.59M | 1.46M | 762,076 | 8.71M | 8.70M |
| Balance sheet | |||||
| Cash & equivalents | $5.02M | $11.31M | $2.90M | $15.30M | $28.68M |
| Short-term investments | — | — | — | — | $0 |
| Receivables | $32,000 | $30,000 | $33,000 | $152,000 | $0 |
| Inventory | $0 | $0 | $297,000 | $0 | — |
| Current assets | $6.63M | $12.13M | $3.94M | $17.05M | $29.53M |
| PP&E, net | $206,000 | $419,000 | $669,000 | $902,000 | $662,000 |
| Total assets | $7.39M | $14.65M | $6.35M | $20.31M | $33.30M |
| Current liabilities | $2.79M | $3.74M | $1.86M | $3.67M | $1.38M |
| Total liabilities | $8.48M | $4.16M | $2.75M | $4.98M | $3.09M |
| Shareholders' equity | -$1.10M | $10.49M | $3.60M | $15.33M | $30.21M |
| Shares outstanding | 2.89M | 1.90M | 839,814 | 8.72M | 8.71M |
| Cash flow statement | |||||
| Operating cash flow | -$10.83M | -$9.46M | -$14.65M | -$12.41M | -$8.45M |
| Capital expenditure | $0 | $13,000 | $42,000 | $396,000 | $409,000 |
| Free cash flow | -$10.83M | -$9.47M | -$14.70M | -$12.80M | -$8.86M |
| Investing cash flow | $94,000 | $9.03M | $816,000 | -$966,000 | -$409,000 |
| Financing cash flow | $4.45M | $8.85M | $1.44M | $0 | $205,000 |
| Depreciation & amortization | $215,000 | $266,000 | $280,000 | $293,000 | $142,000 |
| Stock-based compensation | $303,000 | $532,000 | $1.51M | $2.38M | $2.26M |
| Share buybacks | — | — | — | — | $0 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.